Characterization of eosinophils and natural killer cells in nasal polyps and peripheral blood in eosinophilic chronic rhinosinusitis patients.

[1]  Y. Okamoto,et al.  A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis , 2021, American journal of rhinology & allergy.

[2]  Fuguang Li,et al.  Single-cell transcriptomic analysis reveals the immune landscape of lung in steroid-resistant asthma exacerbation , 2021, Proceedings of the National Academy of Sciences.

[3]  S. Fujieda,et al.  The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. , 2020, Allergology international : official journal of the Japanese Society of Allergology.

[4]  G. Canonica,et al.  Interleukin-5 in the Pathophysiology of Severe Asthma , 2019, Front. Physiol..

[5]  Y. Okamoto,et al.  Amphiregulin‐Producing Pathogenic Memory T Helper 2 Cells Instruct Eosinophils to Secrete Osteopontin and Facilitate Airway Fibrosis , 2018, Immunity.

[6]  R. Terracciano,et al.  Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma , 2018, BioMed research international.

[7]  H. Nakajima,et al.  Allergic airway inflammation: key players beyond the Th2 cell pathway , 2017, Immunological reviews.

[8]  Evan Z. Macosko,et al.  Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets , 2015, Cell.

[9]  F. Malavasi,et al.  Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells. , 2014, Journal of immunological methods.

[10]  C. Mackay,et al.  MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. , 2010, The Journal of allergy and clinical immunology.